Keyword Analysis & Research: keynote 022 melanoma

nih.gov

https://pubmed.ncbi.nlm.nih.gov/33361337/

WebMethods: The double-blind, phase 2 part of KEYNOTE-022 enrolled patients with previously untreated BRAF V600E/K-mutated advanced melanoma from 22 sites in seven countries. … Author: Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, Victoria Atkinson, Henrik Schmi... Publish Year: 2020

Author: Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, Victoria Atkinson, Henrik Schmi...

Publish Year: 2020

DA: 29 PA: 31 MOZ Rank: 81

bmj.com

https://jitc.bmj.com/content/8/2/e001806

WebDec 1, 2020 · KEYNOTE-022 was a five-part, multicenter, phase 1/2 dose-finding and preliminary efficacy study of pembrolizumab plus dabrafenib … Author: Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, Victoria Atkinson, Henrik Schmi... Publish Year: 2020

Author: Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, Victoria Atkinson, Henrik Schmi...

Publish Year: 2020

DA: 69 PA: 20 MOZ Rank: 53

ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.9516

WebJun 2, 2022 · Background: KEYNOTE-022 (NCT02130466) was a phase 1/2 study of pembro + dab + tram or pembro + tram in patients (pts) with unresectable stage III/IV melanoma …

DA: 97 PA: 80 MOZ Rank: 16

ejcancer.com

https://www.ejcancer.com/article/S0959-8049(21)00621-3/fulltext

WebNov 17, 2021 · KEYNOTE-022 (ClinicalTrials.gov, NCT02130466) is a five-part phase 1/2 study that investigated pembrolizumab plus dabrafenib … Female: 26 (62) Male: 16 (38)

Female: 26 (62)

Male: 16 (38)

DA: 26 PA: 51 MOZ Rank: 97

nih.gov

https://pubmed.ncbi.nlm.nih.gov/34801354/

WebObjectives: Parts 4 and 5 of the phase 1/2 KEYNOTE-022 study investigated the maximum tolerated dose (MTD), safety, and efficacy of pembrolizumab plus trametinib in solid …

DA: 42 PA: 63 MOZ Rank: 45

merck.com

https://www.merck.com/news/new-data-for-keytruda-pembrolizumab-in-combination-with-talimogene-laherparepvec-dabrafenib-plus-trametinib-or-low-dose-ipilimumab-in-advanced-melanoma-presented-at-2016-asco-annual-meeting/

WebJun 5, 2016 · MASTERKEY-265, KEYNOTE-022, and KEYNOTE-029, respectively, are included. in the 52 nd Annual Meeting of the American Society of. Clinical Oncology (ASCO) …

DA: 55 PA: 92 MOZ Rank: 70

annalsofoncology.org

https://www.annalsofoncology.org/article/S0923-7534(19)49699-3/fulltext

WebKEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma - Annals …

DA: 42 PA: 17 MOZ Rank: 42

researchgate.net

https://www.researchgate.net/publication/347972716_KEYNOTE-022_part_3_A_randomized_double-blind_phase_2_study_of_pembrolizumab_dabrafenib_and_trametinib_in_BRAF-mutant_melanoma

WebNov 30, 2020 · KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. December 2020. …

DA: 40 PA: 11 MOZ Rank: 37

escholarship.org

https://escholarship.org/uc/item/3h1744t9

WebMature results on PFS, duration of response (DOR), and overall survival (OS) are reported. The double-blind, phase 2 part of KEYNOTE-022 enrolled patients with previously untreated …

DA: 71 PA: 39 MOZ Rank: 61

sciencedirect.com

https://www.sciencedirect.com/science/article/abs/pii/S0959804921006213

WebJan 1, 2022 · KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation - ScienceDirect. …

DA: 64 PA: 27 MOZ Rank: 47